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Abstract
Advances in cancer immunotherapy are leading to its increasing and successful application for the treatment of
solid–tissue cancers. Despite the recent advances there are still significant barriers, in particular, evidence for
significant tumor heterogeneity, both genetic and epigenetic that limit long-term efficacy. Subpopulations of
“stem-like” tumor cells have been identified in nearly all human malignancies based on both morphologic and
functional criteria. Also called cancer stem cells or CSCs, these quiescent cells display enhanced tumorigenic
potential and are capable of repopulating tumors in the wake of traditional cytoreductive therapies. These CSCs
may be best targeted via immunotherapy. Our lab has identified activated natural killer (NK) cell-based therapy as
an effective method to target CSCs particularly after radiation therapy for solid tumors. Using a variety of in vitro
and in vivo methods, including the utilization of primary tumor tissue and patient-derived xenografts, we observed
that autologous and allogeneic NK cells possess the ability to preferentially kill stem-like cells or CSCs from freshly
isolated patient samples representing a broad spectrum of tumor types, including pancreatic cancers, breast
cancers, and sarcomas. The results indicated that CSCs express stress ligand molecules capable of being targeted by
NKG2D on NK cells and that prior radiation therapy can both deplete the cycling non-CSCs bulk tumor population
and upregulate these stress ligands on the CSC making this an effective combination approach.
Background
Recent strategies to activate and engage the immune
system have led to significant breakthroughs in cancer
therapy. The recent success of checkpoint blockade
therapy, targeting the immune-inhibitory proteins PD-1
and/or CTLA-4, has initiated a paradigm shift in the
clinical and preclinical investigation and use of immuno-
therapy for solid tumors. However, despite the impres-
sive clinical efficacy of the most recent iterations of
these therapies, there are still significant issues that
remain. Stem-like tumor cells, also known as cancer
stem cells (CSCs), are present in numerous
hematological and solid malignancies [1, 2]. However,
there is considerable debate regarding how to properly
characterize these cells, whether they exist as a discrete
subpopulation or are a plastic phenotype under epigen-
etic control, and a variety of correlative marker systems
have been suggested for various tissue types. Classically,
a very small fraction of CSCs possesses the ability to
form aggressively growing, heterogeneous, tumors in im-
munodeficient mice or in long-term in vitro outgrowth
assays. Depending on the tissue of origin, the cell surface
markers CD133, CD24/CD44, as well as high expression
of aldehyde dehydrogenase (ALDH) delineates these
cells from their more differentiated and rapidly dividing
progeny. Additionally, the use of extensively cultured
commercial cell lines to study these cells does not accur-
ately represent the heterogeneity found within primary
human tumors, where the epigenetic influence of certain
microenvironmental factors, such as hypoxia and/or in-
flammation exists [3]. To combat this discrepancy, con-
clusions drawn from tumor cell lines are being
increasingly supported by data using human primary
tumor tissues. We, and others, observed that despite re-
duction in overall tumor size with conventional therap-
ies, such as radiotherapy, chemotherapy, and small
molecule inhibitors, residual stem-like tumor cells re-
main, which have the ability to repopulate the tumor
mass and seed metastases [4–7]. An immune approach
to target this population of cells is likely to fill an unmet
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need, since unlike chemotherapy, targeted small mol-
ecule therapy, and radiotherapy; immune cells do not
need tumor cell targets to be actively cycling in order
to mediate their effects. We postulated that the use
of immunotherapy after such regimens are applied
may allow for greater CSC targeting, particularly
when used after cytoreductive therapies.
Main text
Our laboratory has explored the use of natural killer
(NK) cells in the recognition and targeting of CSCs in
several human solid cancers. NK cells are terminally
differentiated innate lymphoid cells with the ability to
spontaneously kill virally-infected or malignant cells
without prior immunization in an MHC-unrestricted
manner. As an adoptive immunotherapy, NK cells have
primarily been used against hematologic cancers as
results with solid tissue tumors have been disappointing
[8–10]. The goal of our studies was to determine if NK
cells would selectively identify and lyse stem-like tumor
cells and to understand how this potential recognition
occurs. NK cells have been long known for their unique
ability to reject allogeneic hematopoietic stem cells, but
not solid tissue allografts. Previous data from our labora-
tory demonstrated that NK cells reject embryonic stem
cells in an NKG2D-dependent manner and thus, we
sought to apply this same rationale to evaluate their
potential to target CSCs [11]. We have demonstrated
that certain small molecule drugs and radiation therapy
enrich for populations of tumor cells that harbor stem-
like qualities and may possibly sensitize these CSCs to
NK cell attack [4, 6].
In our initial evaluation, we screened several human
breast, brain, pancreas, and sarcoma tumor cell lines for
their susceptibility to cytokine-activated NK cell-mediated
cytotoxicity [12]. Using flow cytometry, we observed
that activated allogeneic NK cells significantly killed
stem-like tumor cells expressing high amounts of the
CSC-associated proteins ALDH, CD133, CD24, or CD44.
Importantly, our cell line data was mirrored when we eval-
uated a panel of primary tumor cells derived from freshly
excised patient samples. These primary tissue samples
were tested within 48 h after surgical resection and were
comprised of unsorted cells from multiple subtypes of
sarcoma as well as multiple pancreatic adenocarcinoma
samples. It is important to note that while NK cells
demonstrated the capacity to kill both the CSC and non-
CSC populations, the greatest decreases in the overall
frequency of cells before and after NK killing occurred
within the CSCs. In order to address the possibility of
patient/donor MHC mismatching contributing to the
CSC killing we observed, we also compared autolo-
gous versus allogeneic NK cell activity. We observed
similar efficacy in the ability of activated NK cells to
lyse stem-like targets in vitro although since these
cells were highly cytokine-activated first, it does not
rule out potential differences with lower activation.
Other groups have noted that certain populations of
stem-like tumor cells express various ligands for NK
cell activating receptors [13]. We observed that CSCs
from multiple solid tumors expressed ligands for the
NK cell activating receptor NKG2D, and that blocking
NKG2D using Fc-chimeric proteins abrogated the NK
killing in vitro. Lastly, in order to evaluate the transla-
tional potential of the effects we observed in vitro, we
implanted NSG mice with human tumor xenografts
and evaluated the effects of adoptively transferred NK
cells to eliminate stem-like cells in vivo. Paralleling
our in vitro results, we observed that activated allo-
geneic NK cells significantly reduced the frequencies
of CSCs, reduced the colony forming capacity of
treated tumor cells ex vivo, and delayed the growth of
orthotopic pancreatic xenograft tumors. Importantly,
we have also recently observed that combining NK cell
therapy with prior local tumor irradiation markedly
enhances these effects, indicating that for optimal
efficacy that elimination of the non-CSC populations
needs to occur [4].
Conclusions
Immunotherapies appear to have promise for the goal of
attacking the heterogeneity of cancers based on the
ability of immune cells to indiscriminately kill tumor
cells in different phases of the cell cycle, unlike trad-
itional chemotherapy and radiotherapy. It is apparent
that heterogeneity within cancer exists with subpopula-
tions of stem-like cells or CSCs exhibiting resistance to
conventional cytoreductive therapies possibly due to
quiescence as well as other pathways. Immunotherapy
with T cells often results in antigen-loss variants within
the tumor. We have demonstrated that activated NK
cells may be uniquely capable of targeting CSCs of solid
tissue cancers via stress ligand recognition. Future stud-
ies will need to evaluate the immunological impact of
NK cell killing of CSCs using immunocompetent models
as this may aid in augmenting later T cell responses. It
will also be critical to optimize NK cell immunotherapy
with regard to sustained in vivo effects as the highly acti-
vated NK cells are dependent on cytokines for continued
function and survival. Greater targeting of CSCs by the NK
cells, possibly through monoclonal antibodies may also in-
crease efficacy. It is likely that NK cells need to be applied
using a combination therapy approach as reduction of non-
CSCs, which comprise the bulk of the tumor, needs to
occur. As our understanding of the nature of the stem-
like or CSC subpopulations continues to evolve, so too
will our ability to apply immunotherapy more
effectively.
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